


**Product Name** : PLX5622  
**Cat. No.** : PC-62741  
**CAS No.** : 1303420-67-8  
**Molecular Formula** : C<sub>21</sub>H<sub>19</sub>F<sub>2</sub>N<sub>5</sub>O  
**Molecular Weight** : 395.414  
**Target** : c-Fms (CSF1R)  
**Solubility** :



## Biological Activity

PLX5622 (PLX-5622) is a potent, selective, orally active inhibitor of **CSF1R tyrosine kinase (c-Fms)** activity with  $K_i$  of 5.9 nM, 60-fold less potency against KIT; displays least 50-fold selectivity over 4 related kinases, and over 100-fold selectivity against a panel of 230 kinases; prevents microglial plaque association and improves cognition in 3xTg-AD mice, also depletes microglia and alleviates the catatonic symptoms of Cnp mutants.

Rheumatoid Arthritis

Phase 1 Discontinued

## References

- Janova H, et al. *J Clin Invest*. 2018 Feb 1;128(2):734-745.  
Spangenberg E, et al. *Nat Commun*. 2019 Aug 21;10(1):3758.  
Dagher NN, et al. *J Neuroinflammation*. 2015 Aug 1;12:139.  
Valdearcos M, et al. *Cell Rep*. 2014 Dec 24;9(6):2124-38.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com